Clinical Study
PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance
Table 2
Comparison of clinical parameters after fenofibrate treatment for 12 and 24 weeks in patients with hypertriglyceridemia ().
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Data are means ± SD unless indicated otherwise. TG, FINS, hsCRP, HOMA-IR, and HOMA- are shown as medians and upper and lower quartiles. WC: waist circumference; BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β-cell function. Significantly different at versus baseline; significantly different at versus baseline. |